DE69824313D1 - Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen - Google Patents

Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen

Info

Publication number
DE69824313D1
DE69824313D1 DE69824313T DE69824313T DE69824313D1 DE 69824313 D1 DE69824313 D1 DE 69824313D1 DE 69824313 T DE69824313 T DE 69824313T DE 69824313 T DE69824313 T DE 69824313T DE 69824313 D1 DE69824313 D1 DE 69824313D1
Authority
DE
Germany
Prior art keywords
compound
formula
orlistat
pharmaceutical compositions
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69824313T
Other languages
English (en)
Other versions
DE69824313T2 (de
Inventor
John Heal
Christine Jackson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Abbott GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott GmbH and Co KG filed Critical Abbott GmbH and Co KG
Application granted granted Critical
Publication of DE69824313D1 publication Critical patent/DE69824313D1/de
Publication of DE69824313T2 publication Critical patent/DE69824313T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DE69824313T 1997-12-24 1998-12-16 Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen Expired - Fee Related DE69824313T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9727131 1997-12-24
GBGB9727131.6A GB9727131D0 (en) 1997-12-24 1997-12-24 Therapeutic agents
PCT/EP1998/008249 WO1999033450A2 (en) 1997-12-24 1998-12-16 Pharmaceutical composition containing sibutramine and orlistat

Publications (2)

Publication Number Publication Date
DE69824313D1 true DE69824313D1 (de) 2004-07-08
DE69824313T2 DE69824313T2 (de) 2005-08-25

Family

ID=10824083

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69824313T Expired - Fee Related DE69824313T2 (de) 1997-12-24 1998-12-16 Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen

Country Status (26)

Country Link
US (1) US6403641B2 (de)
EP (1) EP1039900B1 (de)
JP (1) JP2001527036A (de)
KR (1) KR20010033531A (de)
CN (1) CN1134257C (de)
AT (1) ATE268174T1 (de)
AU (1) AU758181B2 (de)
BG (1) BG104568A (de)
BR (1) BR9814498A (de)
CA (1) CA2315259A1 (de)
CZ (1) CZ20002392A3 (de)
DE (1) DE69824313T2 (de)
DK (1) DK1039900T3 (de)
ES (1) ES2222001T3 (de)
GB (1) GB9727131D0 (de)
HK (1) HK1034446A1 (de)
HU (1) HUP0300615A3 (de)
IL (1) IL136733A (de)
NO (1) NO20003313L (de)
NZ (1) NZ505686A (de)
PL (1) PL342099A1 (de)
PT (1) PT1039900E (de)
SK (1) SK9492000A3 (de)
TR (1) TR200001869T2 (de)
UA (1) UA70310C2 (de)
WO (1) WO1999033450A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
GB9914744D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
SI1307264T1 (en) 2000-07-28 2005-02-28 F. Hoffmann-La Roche Ag New pharmaceutical composition
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US6730319B2 (en) * 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
CA2530634A1 (en) * 2003-06-12 2004-12-23 Menachem Rubinstein Methods of treating obesity and related disorders using tellurium and selenium compounds
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
AU2005239788A1 (en) 2004-05-10 2005-11-17 University Of Copenhagen Flaxseeds for body weight management
US9066536B2 (en) 2007-09-12 2015-06-30 University Of Copenhagen Compositions and methods for increasing the suppression of hunger and reducing the digestibility of non-fat energy satiety
US20090214682A1 (en) * 2008-02-22 2009-08-27 Heuer Marvin A Composition and methods for weight loss in a subject
JP5738011B2 (ja) * 2011-03-04 2015-06-17 株式会社ブリヂストン 二次電池の非水電解液用添加剤、二次電池用非水電解液及び非水電解液二次電池
CN102872062A (zh) * 2011-07-13 2013-01-16 鲁南制药集团股份有限公司 一种治疗或预防肥胖症以及代谢综合症的药物组合物
JP2013147488A (ja) * 2011-12-21 2013-08-01 Taisho Pharmaceutical Co Ltd 固形製剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
GB8531071D0 (en) 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
TW381025B (en) 1993-08-05 2000-02-01 Hoffmann La Roche Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
US5459164A (en) 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment

Also Published As

Publication number Publication date
PT1039900E (pt) 2004-09-30
DE69824313T2 (de) 2005-08-25
CZ20002392A3 (cs) 2002-01-16
WO1999033450A3 (en) 1999-09-02
NO20003313L (no) 2000-08-11
ES2222001T3 (es) 2005-01-16
SK9492000A3 (en) 2001-07-10
WO1999033450A2 (en) 1999-07-08
IL136733A0 (en) 2001-06-14
TR200001869T2 (tr) 2000-10-23
NO20003313D0 (no) 2000-06-23
DK1039900T3 (da) 2004-10-04
AU758181B2 (en) 2003-03-20
CN1134257C (zh) 2004-01-14
HUP0300615A2 (hu) 2003-07-28
US20020010160A1 (en) 2002-01-24
BR9814498A (pt) 2000-10-10
EP1039900A2 (de) 2000-10-04
ATE268174T1 (de) 2004-06-15
CN1284872A (zh) 2001-02-21
KR20010033531A (ko) 2001-04-25
GB9727131D0 (en) 1998-02-25
IL136733A (en) 2004-08-31
EP1039900B1 (de) 2004-06-02
PL342099A1 (en) 2001-05-21
US6403641B2 (en) 2002-06-11
BG104568A (bg) 2001-02-28
HUP0300615A3 (en) 2005-04-28
CA2315259A1 (en) 1999-07-08
HK1034446A1 (en) 2001-10-26
NZ505686A (en) 2002-07-26
JP2001527036A (ja) 2001-12-25
AU2273899A (en) 1999-07-19
UA70310C2 (uk) 2004-10-15

Similar Documents

Publication Publication Date Title
DE69824313D1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
CY1107391T1 (el) Αρυλσυμπυκνωμενες αζαπολυκυκλικες ενωσεις
LU91254I2 (fr) Daptomycine et ses dérivés pharmaceutiquement acceptables (cubicinr)
DK0869808T3 (da) Anvendelse af Glu-Trp-dipeptider til fremstilling af et lægemiddel til behandling af forskellige tilstande, der involverer neovaskularisation
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
FI934983A0 (fi) Kinuklidinderivat foer behandling av inflammatoriska och gastrointestinala sjukdomar
NO20022014L (no) En fast oral kontrollert frigjorende doseringsform inneholdende hydrokodon
GEP20043269B (en) Purine Derivatives, Method for Their Production and Composition Containing the Same
MX9707453A (es) Derivados de quinazolina.
SE9504661D0 (sv) New compounds
DK0503440T3 (da) Sumatriptanholdige lægemidler
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
WO2005056524A3 (en) Therapeutic agents useful for treating pain
TR200103613T2 (tr) Burun içinden tatbik edilen morfini içeren farmasötik formülasyonlar ve yöntemler.
LV12291A (lv) Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai
SE0300908D0 (sv) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
DK0998287T3 (da) Anvendelse af levobupivacain
TR200003122T2 (tr) Aril bağlı azapolisiklik bileşikler
GEP20043227B (en) 5HT1 Antagonists for Antidepressant Therapy
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat
NO20031410L (no) Anvendelse av distamycinderivater for fremstilling av medikamenter
SE9504662D0 (sv) New compounds
BG106209A (en) Therapeutic agents

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee